By Dr Carole Abigail Harris

Book Chapters

Goldstein D; Harris C; Harris C, 2008, 'Advances in treatment options for patients with pancreatic cancer', in Touch Briefings Asia Pacific

Journal articles

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Pook DW; Harris CA; Link E; Goh JC; Parnis F; Gurney H; Kichenadasse G; Underhill C; Torres J; Roncolato F; Inderjeeth AJ; Conduit C; McJannett MM; Davis ID; Gedye C, 2024, 'UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802).', Journal of Clinical Oncology, 42, pp. 428 - 428, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.428

Caperchione CM; English M; Sharp P; Agar MR; Phillips JL; Liauw W; Harris CA; McCullough S; Lilian R, 2023, 'Exploring the practicality and acceptability a brief exercise communication and clinician referral pathway in cancer care: a feasibility study', BMC Health Services Research, 23, http://dx.doi.org/10.1186/s12913-023-10003-x

Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C, 2023, 'Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia', Asia-Pacific Journal of Clinical Oncology, 19, pp. 585 - 595, http://dx.doi.org/10.1111/ajco.14001

Albiges L; Beckermann K; Miller WH; Goh JC; Gajate P; Harris CA; Suárez C; Peer A; Park SH; Stadler WM; Weickhardt AJ; Faust G; Fong PCC; Waddell T; Venugopal B; Yin L; Wang D; Perini RF; Powles T, 2023, 'Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.', Journal of Clinical Oncology, 41, pp. 4553 - 4553, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4553

Gedye C; Harris CA; Stockler MR; Morris M; Ferguson T; Goh JCH; Martin A; Underhill CR; Pook D; Krieger LEM; Kichenadasse G; Joshi AJ; Subramaniam S; Zebic DS; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Davis ID, 2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. S1014 - S1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116

Caperchione CM; Stolp S; Phillips JL; Agar M; Sharp P; Liauw W; Harris CA; McCullough S; Lilian R, 2022, 'Cancer survivors’ exercise beliefs, knowledge, and behaviors: An Australian National Survey', Asia-Pacific Journal of Clinical Oncology, 18, pp. 625 - 633, http://dx.doi.org/10.1111/ajco.13729

Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK; Ferguson TR; Lin TP; Chevreau C; Burke JM; Doshi G; Melichar B; Topart D; Oudard S; Kopyltsov E; Hammers HJ; Alva A; Menezes JDJ; Silva AGE; Winquist EW; Hamzaj A; Procopio G; Karaszewska B; Nowakowska-Zajdel EM; Alekseev BY; Gafanov RA; Izmailov A; Semenov A; Afanasyev SG; Lipatov ON; Srinivas S; McDermott D; Kochuparambil ST; Davis ID; Peltola K; Sabbatini R; Chung J; Shkolnik MI; Matveev VB; Gajate Borau P; McCune S; Hutson TE; Dri A; Sales SC; Yeung C; Alcala Castro CM; Bostrom P; Laguerre B; Buttigliero C; de Giorgi U; Fomin EA; Zakharia Y; Hwang C; Singer EA; Yorio JT; Waterhouse D; Kowalyszyn RD; Alfie MS; Yanez Ruiz E; Buchler T; Kankaanranta K; Ferretti G; Kimura G; Nishimura K; Masumori N; Tamada S; Kato H; Kitamura H; Danielewicz I; Wojcik-Tomaszewska J; Sala Gonzalez N; Chiu KY; Atkins MB; Heath E; Rojas-Uribe GA; Gonzalez Fernandez ME; Feyerabend S; Pignata S; Numakura K; Cybulska Stopa B, 2022, 'Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 23, pp. 1133 - 1144, http://dx.doi.org/10.1016/S1470-2045(22)00487-9

Caperchione CM; Sharp P; Phillips JL; Agar M; Liauw W; Harris CA; Marin E; McCullough S; Lilian R, 2022, 'Bridging the gap between attitudes and action: A qualitative exploration of clinician and exercise professional's perceptions to increase opportunities for exercise counselling and referral in cancer care', Patient Education and Counseling, 105, pp. 2489 - 2496, http://dx.doi.org/10.1016/j.pec.2021.11.002

Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H, 2022, 'Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review', Immunotherapy, 14, pp. 511 - 520, http://dx.doi.org/10.2217/imt-2021-0225

Kasherman L; Siu DHW; Woodford R; Harris CA, 2022, 'Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future', Cancers, 14, http://dx.doi.org/10.3390/cancers14061406

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2021, 'Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy', Gait and Posture, 89, pp. 178 - 185, http://dx.doi.org/10.1016/j.gaitpost.2021.07.010

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Link E; Davis ID, 2021, 'Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4565

Gedye C; Joshi AJ; Zhang AY; Martin AJ; Joshua AM; Harris CA; Underhill C; Pook DW; Toner GC; Kichenadasse G; So JY; Goh JC; Morris MF; Lawrence NJ; Ferguson T; Vasey PA; Prithviraj P; Subramaniam S; Stockler MR; Davis ID, 2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS367

Agar M; Caperchione C; Harris C; Liauw W; Lillian R; McCullough S; Phillips J; Sharp P, 2021, 'Bridging the gap between attitudes and action: Opportunities for the cancer care workforce to support exercise counselling and referral', Journal of Science and Medicine in Sport, 24, pp. S13 - S13, http://dx.doi.org/10.1016/j.jsams.2021.09.042

Siu HW; O'Neill R; Tong M; Hong J; Harris CA; Aghmesheh M; Soudy H, 2020, 'IMMUNE CHECKPOINT INHIBITOR INDUCED OVERLAPPING CARDIAC AND NEUROMUSCULAR TOXICITIES: HIGHLIGHT OF EARLY DIAGNOSIS, EARLY INITIATION OF IMMUNOSUPPRESSIVE THERAPY AND MULTIDISCIPLINARY MANAGEMENT', JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8, pp. A178 - A179, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0292

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia-Pacific Journal of Clinical Oncology, 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL, 2011, 'A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer', European Journal of Cancer, 47, pp. 1343 - 1354, http://dx.doi.org/10.1016/j.ejca.2011.03.031

Harris CA; Ward RL; Dobbins TA; Drew A; Pearson S, 2011, 'The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis', Annals of Oncology, 22, pp. 1308 - 1317, http://dx.doi.org/10.1093/annonc/mdq593

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7

Conference Papers

Szwajcer A; Katalinic N; Siu HWD; Wright K; Way M; Harris CA, 2021, 'Knowledge and understanding of the role and feasibility of exercise during and after breast cancer treatment', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 194 - 194, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kasherman L; Harris C; Zhao J; Morris D; Liauw W, 2015, 'OUTCOMES OF OVARIAN CANCER PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HEATED INTRA-PERITONEAL CHEMOTHERAPY (HIPEC): A SINGLE-INSTITUTION EXPERIENCE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 55 - 55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Daniels B; Ward R; Pearson S-A, 2014, 'Do Pharmaceutical Claims Accurately Reflect Oncology Prescribing Practice: Evidence from an Australian HER2+Early Breast Cancer Cohort (HER2EBC)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 465 - 466, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600858&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Ward R, 2014, 'HER2 Positive Early Breast Cancer (HER2EBC): An Australian Patterns of Care Study', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 468 - 468, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600863&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris CA; Ward RL; Daniels B; Pearson S, 2013, 'Do pharmaceutical claims accurately reflect oncology prescribing practice? Evidence from an Australian HER2+early breast cancer cohort ( HER2EBC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.100

Harris CA; Pearson S; Daniels B; Srasuebkul P; Ward RL, 2013, 'HER2-positive early breast cancer (HER2EBC): An Australian pattern of care study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.101

Pearson S; Srasuebkul P; Harris C; Ward RL; Dobbins TA; Harris C, 2010, 'Trastuzumab treatment outcomes according to concomitant chemotheray regimen: Overall survival of HER2+ metastatic breast cancer patients', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S187 - S187, presented at Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, 19 August 2010 - 22 August 2010, http://dx.doi.org/10.1002/pds

Conference Presentations

Harris C; Daniels B; Ward R; Pearson S-A, 2013, 'DO PHARMACEUTICAL CLAIMS ACCURATELY REFLECT ONCOLOGY PRESCRIBING PRACTICE: EVIDENCE FROM AN AUSTRALIAN HER2+EARLY BREAST CANCER COHORT (HER2EBC)', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Srasuebkul P; Ward R, 2013, 'HER2 POSITIVE EARLY BREAST CANCER (HER2EBC): AN AUSTRALIAN PATTERN OF CARE STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4537 - 4537, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4537

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2021, 'UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.325

Siu HW; O'Neill R; Tong M; Harris C; Hong J; Aghmesheh M; Hussein H, 2020, 'Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management', in Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management, presented at sitc 2020, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0292

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Morris MF; Begbie S; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2020, 'UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page